Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nalmefene HCl in the Treatment of Pathological Gambling

NCT00132119 is registered in ClinicalTrials.gov with Somaxon Pharmaceuticals as lead sponsor.

NCT NCT00132119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00132119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nalmefene HCl in the Treatment of Pathological Gambling
Lead sponsor
Somaxon Pharmaceuticals
Phase
Phase 2/3
Overall status
Completed
Start date
August 31, 2005
Completion date
August 31, 2006
Enrollment
233 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pathological gambling